AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
2002_CD
Group_NN
Financial_NN
Record_NN
US_FPP1
GAAP_NN
www_NN
._.
com_NN
125_CD
Group_NN
Financial_NN
Record_NN
US_FPP1
GAAP_NN
Group_NN
Financial_NN
Record_NN
US_FPP1
GAAP_NN
The_DT
selected_VBN
financial_JJ
data_NN
set_VBN [WZPAST]
out_PIN
below_PLACE
for_PIN
each_QUAN
of_PIN
the_DT
years_NN
in_PIN
the_DT
five_CD
year_NN
period_NN
ended_VBD
31_CD
December_NN
2002_CD
,_,
has_VPRT [PEAS]
been_VBN [PASS]
extracted_VBN
or_CC
derived_VBN
from_PIN
audited_JJ
Financial_NN
Statements_NOMZ
._.
The_DT
selected_VBN
financial_JJ
data_NN
should_NEMD
be_VB [PASS]
read_VBN
in_PIN
conjunction_NOMZ
with_PIN [STPR]
,_,
and_ANDC
are_VPRT [PASS]
qualified_VBN
in_PIN
their_TPP3
entirety_NN
by_PIN
reference_NN
to_TO
,_,
the_DT
Financial_NN
Statements_NOMZ
of_PIN
AstraZeneca_NN
and_CC
the_DT
notes_NN
thereto_RB
,_,
which_WDT [SERE]
are_VPRT [PASS]
included_VBN
elsewhere_RB
in_PIN
this_DEMO
document_NOMZ
._.
Consolidated_NN
income_NN
statement_NOMZ
data_NN
For_PIN
the_DT
years_NN
ended_VBN
31_CD
December_NN
1998 1999 2000 2001_CD
2002_CD
Net_JJ
income_NN
loss_NN
from_PIN
operations_NOMZ
$_$
million_CD
1,036_CD
3,539_CD
865_CD
1,397_CD
2,307_CD
Net_JJ
income_NN
loss_NN
from_PIN
operations_NOMZ
per_PIN
Ordinary_NN
Share_NN
$_$
1.09_CD
$_$
2.26_CD
$_$
0.49_CD
$_$
0.79_CD
$_$
1.33_CD
Diluted_VBN
income_NN
loss_NN
from_PIN
operations_NOMZ
per_PIN
Ordinary_NN
Share_NN
$_$
1.09_CD
$_$
2.26_CD
$_$
0.49_CD
$_$
0.79_CD
$_$
1.33_CD
Net_JJ
income_NN
loss_NN
from_PIN
operations_NOMZ
had_VBD
SFAS_NN
No_NN
141_CD
been_VBN [PASS]
adopted_VBN
1,129_CD
2,833_CD
1,716_CD
2,125_CD
Net_NN
and_CC
diluted_JJ
income_NN
loss_NN
per_PIN
Ordinary_NN
Share_NN
from_PIN
operations_NOMZ
had_VBD
SFAS_NN
No_NN
141_CD
been_VBN [PASS]
adopted_VBN
$_$
1.19_CD
$_$
1.81_CD
$_$
0.97_CD
$_$
1.21_CD
Ratio_NN
of_PIN
earnings_GER
to_PIN
fixed_JJ
charges_NN
For_PIN
the_DT
Group_NN
with_PIN
estimated_VBN [PRIV]
material_NN
adjustments_NOMZ
to_TO
accord_VB
with_PIN
US_FPP1
GAAP_NN
11.7_CD
19.3_CD
15.5_CD
25.0_CD
36.7_CD
Consolidated_NN
balance_NN
sheet_NN
data_NN
At_PIN
31_CD
December_NN
1998 1999 2000 2001_CD
2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Total_JJ
assets_NN
10,675_CD
46,640_CD
41,500_CD
38,081_CD
42,578_CD
Shareholders_NN
equity_NOMZ
5,558_CD
33,735_CD
29,707_CD
27,402_CD
30,183_CD
Merger_NN
accounting_GER
For_PIN
the_DT
purpose_NN
of_PIN
US_FPP1
GAAP_NN
,_,
the_DT
merger_NN
has_VPRT [PEAS]
been_VBN [PASS]
regarded_VBN
as_IN
a_DT
purchase_NN
accounting_GER
acquisition_NOMZ
of_PIN
Astra_NN
by_PIN
Zeneca_NN
._.
Accordingly_RB
the_DT
US_FPP1
GAAP_NN
results_NN
above_PLACE
for_PIN
1998_CD
are_VPRT [PASS]
not_XX0
restated_VBN
for_PIN
the_DT
merger_NN
with_PIN
Astra_NN
and_CC
represent_VB
the_DT
previously_TIME
reported_VBN [PUBV]
results_NN
of_PIN
Zeneca_NN
Group_NN
PLC._NN
._.
Ratio_NN
of_PIN
earnings_GER
to_PIN
fixed_JJ
charges_NN
UK_NN
and_PHC
US_FPP1
GAAP_NN
For_PIN
the_DT
purpose_NN
of_PIN
computing_VBG
these_DEMO
ratios_NN
,_,
earnings_GER
consist_VPRT
of_PIN
the_DT
income_NN
from_PIN
continuing_VBG
ordinary_JJ
activities_NOMZ
before_IN
taxation_NOMZ
of_PIN
Group_NN
companies_NN
and_PHC
income_NN
received_VBN [WZPAST]
from_PIN
companies_NN
owned_VBN
50_CD
%_NN
or_CC
less_JJ
,_,
plus_PIN
fixed_VBN
charges_NN
excluding_VBG [WZPRES]
capitalized_JJ
interest_NN
._.
Fixed_VBN
charges_NN
consist_VPRT
of_PIN
interest_NN
including_VBG [WZPRES]
capitalized_JJ
interest_NN
on_PIN
all_QUAN
indebtedness_NOMZ
,_,
amortisation_NOMZ
of_PIN
debt_NN
discount_NN
and_PHC
expense_NN
and_CC
that_DEMO
portion_NOMZ
of_PIN
rental_JJ
expense_NN
representative_NN
of_PIN
the_DT
interest_NN
factor_NN
._.
The_DT
comparative_JJ
figures_NN
have_VPRT [PEAS]
been_VBN [PASS]
restated_VBN
from_PIN
those_DEMO
previously_TIME
disclosed_VBN [PUBV]
to_TO
reflect_VB [PRIV]
the_DT
reclassification_NOMZ
of_PIN
the_DT
operations_NOMZ
of_PIN
Specialties_NN
and_PHC
Agrochemicals_NN
as_IN
discontinued_VBN
._.
